Clinical trial
A Phase I/II Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.
NCT05713006 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.
- Lead sponsor
- Instituto Nacional de Cancerologia de Mexico
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- May 1, 2022
- Completion date
- December 1, 2027
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alk gene mutation, non-small cell lung cancer stage iiib